Neonc Technologies (NASDAQ:NTHI) Issues Earnings Results

Neonc Technologies (NASDAQ:NTHI) issued its quarterly earnings results on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46), Zacks reports.

Neonc Technologies Stock Performance

NTHI traded down $0.01 during trading hours on Wednesday, hitting $4.34. 541,200 shares of the stock were exchanged, compared to its average volume of 80,690. The stock has a 50-day simple moving average of $4.15 and a 200-day simple moving average of $6.19. Neonc Technologies has a 12 month low of $3.01 and a 12 month high of $12.99.

Key Stories Impacting Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: The Phase 2a study met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% historical standard-of-care benchmark. The result was nearly 2.5 times the benchmark and statistically significant, with a reported p-value of 0.0047. NeOnc Technologies Reports Positive Topline Phase 2a Results
• Positive Sentiment: NEO100 produced median overall survival of 26.09 months, while 86.7% of patients were alive at six months, 60.9% at 12 months and 54.1% at 24 months. Five of 24 patients remained on treatment, including one ongoing partial response lasting more than 114 days. NeOnc’s NEO100 Phase 2a Brain Cancer Study
• Positive Sentiment: The company reported no major toxicities, with adverse events predominantly low-grade, potentially supporting NEO100’s tolerability profile. NeOnc plans to request a Type B meeting with the FDA to discuss a registrational development path. FDA Meeting and NEO100 Clinical Results
• Neutral Sentiment: Trading in NTHI was temporarily halted for pending news before the data release, highlighting the importance of the announcement but also the stock’s event-driven volatility.
• Negative Sentiment: The results come from only 24 patients and rely on a historical benchmark, so larger controlled studies and FDA discussions remain necessary. Separately, NeOnc’s latest quarterly report showed an adjusted loss of $0.58 per share, substantially worse than the $0.12 consensus estimate, underscoring ongoing financial and execution risks.

Institutional Trading of Neonc Technologies

Several hedge funds have recently bought and sold shares of NTHI. Bank of America Corp DE acquired a new position in shares of Neonc Technologies during the 2nd quarter valued at $801,000. Vanguard Group Inc. acquired a new position in Neonc Technologies during the third quarter valued at $1,279,000. 683 Capital Management LLC acquired a new stake in Neonc Technologies during the 4th quarter worth about $442,000. Royal Bank of Canada purchased a new position in Neonc Technologies during the first quarter valued at approximately $247,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Neonc Technologies in the fourth quarter worth $126,000.

Wall Street Analysts Forecast Growth

NTHI has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a report on Tuesday, May 26th. Weiss Ratings downgraded Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 24th. Maxim Group assumed coverage on Neonc Technologies in a research report on Monday, May 18th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Alliance Global Partners initiated coverage on Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Neonc Technologies presently has a consensus rating of “Hold” and an average price target of $16.00.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.